Announcement from the Nomination Committee concerning the Annual General Meeting 2017

The Nomination Committee has been consisting of Axel Calissendorff, Chairman (appointed by Flerie Participation AB), Lars Backsell (Chairman of the Board of Directors of Recipharm), Johan Lannebo (appointed by Lannebo Fonder) and Ossian Ekdahl (appointed by Första AP-fonden).

The Nomination Committee proposes the re-election of all board members: Lars Backsell, Anders G. Carlberg, Marianne Dicander Alexandersson, Thomas Eldered, Helena Levander, Wenche Rolfsen, Tony Sandell and Carlos von Bonhorst.

The Nomination Committee also proposes the re-election of Lars Backsell as Chairman of the Board of Directors.

The Nomination Committee’s other proposals, such as election of the Chairman of the Meeting, remuneration for the board members and the auditor as well as election of the auditor, will be announced in the notice to convene the Annual General Meeting.

Recipharm’s Annual General Meeting will be held on 10 May 2017 at 2 pm at Klara Konferens, Vattugatan 6 in Stockholm, Sweden.
 

For further information please contact:
Axel Calissendorff, Chairman of the Nomination Committee, telephone: +46 768 40 91 03
or
Lars Backsell, Chairman of the Board of Directors and member of the Nomination Committee, telephone: +46 8 602 52 00  
 

About Recipharm
Recipharm is a leading Contract Development and Manufacturing Organisation (CDMO) in the pharmaceutical industry employing around 5 000 employees. Recipharm offers manufacturing services of pharmaceuticals in various dosage forms, production of clinical trial material and APIs, and pharmaceutical product development. Recipharm manufactures several hundred different products to customers ranging from big pharma to smaller research and development companies. Recipharm’s turnover is approximately SEK 5.3 billion and the Company operates development and manufacturing facilities in France, Germany, India, Israel, Italy, Portugal, Spain, Sweden, the UK and the US and is headquartered in Stockholm, Sweden. The Recipharm B-share (RECI B) is listed on Nasdaq Stockholm.

For more information on Recipharm and our services, please visit www.recipharm.com  

Recipharm AB (publ)
Corporate identity number 556498-8425
Address Box 603, SE-101 32 Stockholm, Sweden,  Telephone  +46 8 602 52 00

www.recipharm.com

Tags:

About Us

About RecipharmRecipharm is a leading CDMO (Contract Development and Manufacturing Organisation) in the pharmaceutical industry employing some 5 000 employees. Recipharm offers manufacturing services of pharmaceuticals in various dosage forms, production of clinical trial material and APIs, and pharmaceutical product development. Recipharm manufactures several hundred different products to customers ranging from Big Pharma to smaller research- and development companies. Recipharm’s turnover is approximately SEK 5.3 billion and the company operates development and manufacturing facilities in France, Germany, India, Israel, Italy, Portugal, Spain, Sweden, the UK and the US and is headquartered in Stockholm, Sweden. The Recipharm B-share (RECI B) is listed on Nasdaq Stockholm. For more information on Recipharm and our services, please visit www.recipharm.com

Subscribe

Documents & Links